Comparative analysis of mRNA and inactivated COVID-19 vaccines: A study from Faisalabad district of Pakistan

Abstract

Background:

Pakistan has vaccinated over 122 million people. The two vaccines in widespread use are inactivated (BBIBP-CorV & Sinovac) and mRNA forms (BNT162b2 & mRNA-1273). The primary aim of this study was to compare these two forms of vaccines against unvaccinated individuals collectively and then to see which one is more efficacious.

Methods:

Case–control study design was used to compare the efficacy of inactivated and mRNA vaccines against symptomatic infection, hospitalisations and mortality due to Severe Acute Respiratory Syndrome Coronavirus 2 between vaccinated and unvaccinated individuals. We derived recovery time from illness for both vaccines. Furthermore, we also compared the vaccines against similar parameters (symptomatic disease, hospitalisations and mortality). We calculated crude odds ratios for each dependent variable. p value of 0.05 or below was considered significant.

Results:

Vaccinated individuals were significantly protected from hospitalisations and mortality compared to unvaccinated individuals (p < 0.001). There was no difference in protection from symptomatic disease (p = 0.28), hospitalisations (p = 0.59) and mortality (p = 0.53) between two forms of vaccines. mRNA vaccine had better recovery time than all other vaccines (p < 0.001).

Discussion:

Our study showed that vaccinated individuals are at low risk of hospitalisations and mortality even without a booster and both vaccine forms are equally effective at preventing hospitalisations and mortality.

Keywords

COVID-19 mRNA vaccine inactivated vaccine Pakistan infectious disease

Get full access to this article

View all access options for this article.

References

Covid.gov.pk. COVID-19 Health advisory platform by ministry of national health services regulations and coordination. https://covid.gov.pk/stats/pakistan (2022, accessed 7 July 2022).

NADRA. Immunization program. https://www.nadra.gov.pk/ (2022, accessed 7 July 2022).

Covid19.who.int. WHO coronavirus (COVID-19) dashboard. https://covid19.who.int/ (2022, accessed 7 July 2022).

Lytras

Kossyvakis

Melidou

et al. Influenza vaccine effectiveness in preventing hospitalizations with laboratory-confirmed influenza in Greece during the 2014–2015 season: a test-negative study. J Med Virol 2016; 88: 1896–904.

De Serres

Skowronski

et al. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials. Euro Surveill 2013; 18: 20585.

Guan

et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708–20

Centers for Disease Control and Prevention. Understanding mRNA COVID-19 vaccines. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html (2021, accessed 7 July 2022).

Haas

Angulo

McLaughlin

et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021; 397: 1819–29.

Rosenblum

Hadler

Moulia

et al. Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the advisory committee on immunization practices–United States, July 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 1094–9.

10.

Gov.sg. Watch out for misinformation about mRNA and inactivated virus COVID-19 vaccines. https://www.gov.sg/article/watch-out-for-misinformation-about-mrna-and-inactivated-virus-covid-19-vaccines (2022, accessed 7 July 2022).

11.

Centers for Disease Control and Prevention. Comparative effectiveness of moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions–United States, March–August 2021. https://www.cdc.gov/mmwr/volumes/70/wr/mm7038e1.htm (2021, accessed 16 September 2022).

12.

Jara

Undurraga

González

et al. Effectiveness of an inactivated SARS-CoV-2 vaccine. N Engl J Med 2021; 385: 1336–9

13.

Nadeem

ul Munamm

Ur Rasool

et al. Safety and efficacy of Sinopharm vaccine (BBIBP-CorV) in elderly population of Faisalabad district of Pakistan. Postgrad Med J. Epub ahead of print 4 May 2022. DOI: 10.1136/postgradmedj-2022-141649.

14.

European Medicines Agency. Safety of COVID-19 vaccines. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/safety-covid-19-vaccines (2022, accessed 7 July 2022).

15.

Choi

Park

Lee

et al. Variable effects of underlying diseases on the prognosis of patients with COVID-19. PLoS One 2021; 16: e0254258.

16.

Premikha

Chiew

Wei

et al. Comparative effectiveness of mRNA and inactivated whole-virus vaccines against coronavirus disease 2019 (COVID-19) infection and severe disease in Singapore. Clin Infect Dis. Epub ahead of print 12 April 2022. DOI: 10.1093/cid/ciac288.

17.

Thompson

Burgess

Naleway

et al. Prevention of Covid-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med 2021; 385: 1817–21.

18.

Fathizadeh

Afshar

Masoudi

et al. SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: a review. Int J Biol Macromol 2021; 188: 740–50.

19.

Lim

Mak

Leung

et al. Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. Lancet Microbe 2021; 2: e423.

20.

Rotshild

Hirsh-Raccah

Miskin

et al. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep 2021; 11: 22777.

21.

Hashim

Pakistan confirms first case of Omicron COVID variant. https://www.aljazeera.com/news/2021/12/13/pakistan-detects-first-case-of-covid-19-omicron-variant (2022, accessed 7 July 2022).

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.10 MB